The CASSS Bioconjugate Virtual Summit 2026 focuses on the analytical and manufacturing questions that arise when developing antibody-drug conjugates and other bioconjugates. Its “Tackling Bioconjugate Challenges” theme brings together comparability assessment, impurity qualification, charge-variant control and process characterization. The listed presentations also address antibody-oligonucleotide conjugates and risk-based strategies for late-phase ADC development, followed by panel discussions. Scheduled as a one-day virtual program on May 28, 2026, the summit is relevant to analytical scientists, process-development teams, quality-control professionals and CMC or regulatory specialists who need to connect product characterization with manufacturing and regulatory decisions.
Learning Objectives
Upon completion of the summit, participants should be better able to:
- Identify and mitigate comparability risks, such as detecting new low-level heavy-heavy chain variants in Antibody-Drug Conjugates (ADCs).
- Evaluate impurity qualification requirements specifically for drug-linkers and their related impurities used to generate ADCs.
- Develop and characterize manufacturing processes for antibody-oligonucleotide conjugates.
- Manage bioconjugate heterogeneity related to drug-linkers and formulate charge variant control strategies for late-stage ADCs.
- Design risk-based analytical comparability strategies for ADCs navigating late-phase development.
- Apply Chemistry, Manufacturing, and Controls (CMC) regulatory considerations for ADCs from a strict biologics perspective.
Topics
-
Analytical Comparability Approach for an Antibody Drug Conjugate
-
Charge Variant Control Strategy for Late-Stage Antibody Drug Conjugates
-
CMC Regulatory Considerations for Antibody-Drug Conjugates (ADCs) – From the Biologics Perspective
-
Comparability Risk Mitigation Identification of a New Low-Level Heavy-Heavy Chain Variant in an ADC
-
Designing Risk-Based Analytical Comparability Strategic Considerations for Antibody Drug Conjugates in Late-Phase Development
-
Development and Characterization of Antibody-Oligonucleotides Conjugate Manufacturing Processes
-
Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate Antibody-Drug Conjugates
-
Managing Bioconjugate Heterogeneity Related to Drug-Linkers
-
Session I Panel Discussion and Summary Closing Remarks
-
Session II Panel Discussion and Summary Concluding Remarks




